The use of circulating tumour DNA as liquid biopsies in cancer care is rapidly expanding. ctDNA has many potential advantages as it is non-invasive and potentially more efficient and less-costly compared to tissue genotyping. Accurate genotyping of lung cancer is of particular interest in the Australia/NZ due to high rates of targetable mutations in cancers, especially in the Māori and Pacific population1, 2. Furthermore, this technology can improve diagnostic and cancer monitoring in rural communities, where access to hospital-based services can be limited. Data on the current usage and barriers to implementation is needed to support its use in clinical practice.
This study aims to survey assess the current usage of ctDNA in clinical practice and identify barriers to implementation in the Australia/NZ.